Chester County News and Community Website
PHILADELPHIA, PA — The Wistar Institute, led by Dr. David B. Weiner, has announced successful preclinical tests of a groundbreaking immune therapy for glioblastoma, a highly aggressive brain cancer with …
Wistar Institute Develops Promising Immune Therapy for Glioblastoma Read More PHILADELPHIA, PA — The Wistar Institute has made a significant breakthrough in understanding the role of Parkin, a protein traditionally associated with Parkinson’s disease, in the body’s immune response to cancer. …
Wistar Institute Breakthrough: Parkin Protein Revealed as a Game-Changer in Cancer Immunity! Read More
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca UK Limited) for use with carboplatin plus paclitaxel followed by single-agent durvalumab. This approval targets …
FDA Approves New Treatment for Advanced Endometrial Cancer Read More PHILADELPHIA, PA — Hepatocellular carcinoma (HCC), better known as liver cancer, is a particularly aggressive form of cancer that often leaves healthcare providers grappling for treatment options. This cancer’s stealthy …
Novel Vaccine Shows Promising Results in Battle Against Liver Cancer: A New Hope in the Medical Field Read More PHILADELPHIA, PA — The Wistar Institute’s David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center (VIC) and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research, and collaborators, …
Wistar Scientists Engineer New NK cell Engaging Immunotherapy Approaches to Target and Potentially Treat Recalcitrant Ovarian Cancer Read More